Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - K-V Pharmaceutical Co | d8k.htm |
| EX-99.2 - PRESS RELEASE - K-V Pharmaceutical Co | dex992.htm |
| EX-99.1 - PRESS RELEASE - K-V Pharmaceutical Co | dex991.htm |
Exhibit 99.3
FOR IMMEDIATE RELEASE
Contact Information:
Catherine M. Biffignani
Vice President, Investor Relations
314-645-6600
KV PHARMACEUTICAL COMPANY ANNOUNCES DELAY IN CONFERENCE CALL
AND PROVIDES OVERVIEW OF CONFERENCE CALL COMMENTS
February 14, 2011 – St. Louis, MO. – KV Pharmaceutical Company (KVa/KVb) announced that its conference call scheduled for 10:00 am EST will now begin at 11:00 am.
The Company is also providing an overview of its conference call comments on its website and are available at www.kvpharmaceutical.com under Investor Relations/Conference Call.
About K-V Pharmaceutical Company
K-V Pharmaceutical Company is a fully-integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded prescription pharmaceutical products. The Company markets its technology-distinguished products through Ther-Rx Corporation, its branded drug subsidiary.
For further information about K-V Pharmaceutical Company, please visit the Company’s corporate Website at www.kvpharmaceutical.com.